Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer

Kimberley L. Kiong, Fang Yu Lin, Christopher M.K.L. Yao, Theresa Guo, Renata Ferrarotto, Randal S. Weber, Carol M. Lewis

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background: Neoadjuvant chemotherapy (NAC) has been used in patients with advanced head and neck cancers (HNCs) with the intent of downstaging tumors and suppressing distant metastases. However, to the authors' knowledge, the perioperative impact of NAC has not been systematically explored in patients with HNC. The objective of the current study was to compare perioperative outcomes with surgery upfront compared with patients treated with NAC. Methods: Between March 1, 2016, and March 31, 2019, patients undergoing surgery for HNC with flap reconstruction at The University of Texas MD Anderson Cancer Center in Houston were included. Data were extracted from the prospectively maintained National Surgical Quality Improvement Program database. Postoperative complications, return to operating room, and readmission rates were compared. Univariate and multivariate analyses of length of stay and overall and wound complications were performed. Results: A total of 834 patients were analyzed, 687 of whom (82.4%) underwent surgery upfront and 147 of whom (17.6%) received NAC. A total of 631 cases (75.7%) involved the upper aerodigestive tract whereas 203 cases (24.3%) were cutaneous. A total of 317 patients (38.0%) had recurrent disease. The NAC group was younger (P <.001) and had less hypertension (P =.011), but had more advanced clinical stage tumors (P <.001) and surgeries with multiple flap reconstruction (P =.007). Patient groups did not differ with regard to wound complications (P =.47), return to operating room (P =.31), or readmission rates (P =.49). The NAC group received more blood transfusions (P <.001) but was found to have a lower risk of overall complications on multivariate analysis (odds ratio, 0.50; 95% CI, 0.30-0.83). The overall complication rate was unchanged with surgery performed ≤21 days after the last chemotherapy cycle. Conclusions: Patients undergoing NAC appear to have a higher disease burden but tend to be younger and healthier. Within the context of this inherent selection bias, NAC does not appear to increase perioperative morbidity among patients undergoing surgery for HNC.

Original languageEnglish (US)
Pages (from-to)4304-4314
Number of pages11
JournalCancer
Volume126
Issue number19
DOIs
StatePublished - Oct 1 2020

Keywords

  • chemotherapy
  • head and neck neoplasms
  • morbidity
  • surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer'. Together they form a unique fingerprint.

Cite this